Navigation Links
Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
Date:8/29/2007

/p>

will highlight outcomes within the high-risk diabetic subset. The

Company plans to issue a press release at this time.

Tuesday, September 4

-- TAXUS II long-term data. At 9:45 a.m., five-year clinical follow-up

results from the TAXUS II clinical trial will be presented by Antonio

Colombo, M.D., the study's principal investigator, in the Helsinki Room

(Zone 2). TAXUS II is a randomized, double-blind, controlled study of

the safety and efficacy of the TAXUS Paclitaxel-Eluting Coronary Stent,

in which two sequential cohorts of patients with standard risk, de novo

coronary artery lesions were treated with different dose formulations

versus a bare-metal stent control group. The Company plans to issue a

press release at this time.

-- Cardiac Rhythm Management Workshop Session. At 12:45 p.m., the Company

will host a workshop entitled "Cardiac Resynchronisation Therapy: all

you need to know to maximize patient follow-up," in the Cairo Room

(Zone 2). The session will address the current status of CRT, the

value of HF diagnostics after device implant, and hemodynamic

optimization during CRT.

-- Symposium on Drug-Eluting Stents. At 2:00 p.m., the Company will host

a symposium entitled "What's the evidence for using drug-eluting stents

in your patients," chaired by H.D. Glogar, M.D., and Donald S. Baim,

M.D., in the Brussels Room (Zone 4). The symposium will focus on

current treatment options for coronary artery disease, latest

challenges in ULMCA (Unprotected Left Main Coronary Artery) with PCI,

evidence-based medicine for diabetics, real world data, and future

outlook for DES.

Wednesday, September 5

-- TAXUS in Women study. Results from the TAXUS WOMAN study, a gender

specific sub-group analysis of the TAXUS II - VI trials
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boston Scientific Announces Schedule for EuroPcr 2007
2. Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase I/IIa 6-Month Results at 75th Annual Meeting of the American Association of Neurological Surgeons
3. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
4. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
5. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
6. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
7. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
10. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
11. Inspire Announces Presentations at Two European Scientific Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015  Johnson & Johnson (NYSE: ... 10 a.m. (Eastern Time) on Thursday, April 23, 2015, from ... Investors and other interested parties may access ... Company,s website at www.jnj.com and clicking on the ... meeting will be made available a few hours after the ...
(Date:3/27/2015)... 27, 2015  WebMD Health Corp. (NASDAQ: ... health information, today announced an exclusive White ... Action Plan for Combating Antibiotic-Resistant Bacteria . ... urgency and importance of addressing antibiotic-resistant bacteria ... health.    The WebMD interview, available ...
(Date:3/26/2015)... , March 26, 2015 "Whether it,s our ... one day." In a single sentence, ... scientific officer at Pfizer,s Centers for Therapeutic Innovation ... scientists fueling progress at America,s biopharmaceutical companies. ... side-by-side with academia, patient foundations and the National Institutes ...
Breaking Medicine Technology:Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2
... publishes largest study comparing cancer risk of ezetimibe ... -BOSTON, March 25 A new study shows ... ezetimibe/simvastatin combination treatments, compared to cancer rates of ... conducted by Tufts Medical Center lipid and health ...
... N.J., March 25 DOR BioPharma, Inc. (OTC Bulletin ... company, announced today that it has entered into a ... with its clinical trials management partner, Numoda Corporation (Numoda). ... be completed in January 2010. This investment follows ...
Cached Medicine Technology:Ezetimibe and Ezetimibe/Simvastatin Combo Pose No Increased Cancer Risk, Study Shows 2DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation 2DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation 3DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation 4DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation 5
(Date:3/28/2015)... One in three young athletes who undergo ... at the American Orthopaedic Society for Sports Medicine’s ( ... term success of surgery for patients aged 18 years ... 242 patients who underwent ACL reconstruction between 1993 and ... from North Sydney Orthopaedic and Sports Medicine Centre. “Of ...
(Date:3/28/2015)... California (PRWEB) March 28, 2015 Andrew Hawley ... original 1960's Who psychedelic concert posters. The Who and the ... York on August 2, 1968. According to Hawley, “The Who ... many concert halls and college campuses. Perhaps the most famous ... with Jim Morrison and the Doors on August 2, 1968 ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Designers and ... new overlay entitled Scratches 5K from Pixel Film Studios. ... effects to any media inside Final Cut Pro X” ... Corporate saves time and is an effective tool for ... FCPX Overlay Scratches 5K's intuitive grunge overlays. Simply drag ...
(Date:3/27/2015)... The Monogamy Method - ... Sanderson and Jason Rogers has just been released to ... The commotion surrounding the course's launch has caught the ... an in-depth review of the new program. , "Many ... their lives suddenly start pulling away or expressing interest ...
(Date:3/27/2015)... First Choice Emergency Room opened its new Summerwood ... W Lake Houston Pkwy, Houston, Texas and is open 24-7. ... to delivering the highest quality emergency medical care to my ... Choice Emergency Room Summerwood. , To celebrate the ... Creek High School at First Choice Emergency Room’s ribbon cutting ...
Breaking Medicine News(10 mins):Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2Health News:First Choice Emergency Room Opens New Facility in Houston, Texas 2
... with rheumatoid arthritis (RA), the most common chronic ... individuals to experience depression. Although depression in primary ... examined whether rheumatologists and RA patients discuss depression ... the February issue of Arthritis Care & Research ...
... Key to Behavior Change & Decrease in ... Disparities in care of,diabetes patients in ... interventions, according to a new,study published in ... Rates of,glucose control testing among Latinos with ...
... Care and HealthEOS announced today that they have reached an agreement ... ... As a result of the settlement,agreement, WPS customers that use the ... facilities through the end of,2008. The services provided to these WPS ...
... Feb. 1 The Obesity Action,Coalition (OAC) is calling ... House Bill 282 (HB 282) that discriminates,against those affected ... The OAC strongly feels that HB 282 is outright ... often misguided attempts,proposed to address the obesity epidemic., ...
... Association (APHA) today released its annual congressional record,which measures ... to public health., APHA,s report was compiled by ... votes during the first session of the 110th,Congress in ... senators voted in support of APHA,s,position on all eight ...
... - Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division ... retrospective analysis, which demonstrated that ENBREL reduced C-reactive protein ... to severe plaque psoriasis following 12 weeks of treatment. ... greater in the ENBREL treated group compared to the ...
Cached Medicine News:Health News:Depression not discussed during rheumatoid arthritis doctor visits 2Health News:Lumetra Program Improves Diabetes Care Among Latinos 2Health News:Wisconsin Physicians Service Insurance Corporation, Aurora Health Care and HealthEOS Announce Settlement Agreement 2Health News:Obesity Action Coalition Calls on the State of Mississippi House of Representatives to Withdraw House Bill 282 Discriminating Against Those Affected by Obesity 2Health News:APHA Scores Members of Congress on Public Health Voting Record 2Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 2Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 3Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 4Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 5
... a scope designed specifically to enable direct ... also suitable for pediatric applications as well. ... a mere 2.8mm across. As a result, ... accomplished with greater ease. And since this ...
Facilitates one-lung ventilation when using dual lumen endobronchial tubes....
... Double lumen tubes ... ventilation., ,Each ... is packaged with ... adaptors, suction catheters ...
... a double lumen tube made of silicone rubber ... ,Due to the characteristics of silicone rubber, Silbronco ... at insertion. Furthermore, the tube will not soften ... long term surgery., ,Silbronco is also especially ...
Medicine Products: